Evidence map›Paper›PMID 21504384›Full record

ArticleLeukemia & lymphoma2011

PU.1-dependent regulation of UCH L1 expression in B-lymphoma cells.

Anjali Bheda, Wei Yue, Anuradha Gullapalli, Julia Shackelford, Joseph S Pagano

Abstract read
In one paragraph

Article in Leukemia & lymphoma, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. The Epstein-Barr virus noncoding RNA EBER2 transactivates the UCHL1 deubiquitinase to accelerate cell growth.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. UCH-LI acts as a novel prognostic biomarker in gastric cardiac adenocarcinoma.International journal of clinical and experimental pathology · 2015
    Article
  9. Review
  10. Article
  11. Ubiquitin C-terminal hydrolase l1 in tumorigenesis.Biochemistry research international · 2012
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anjali BhedaLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Wei Yue
Anuradha Gullapalli
Julia Shackelford
Joseph S Pagano

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vironomics and Biostatistics CoreP01CA019014 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLOSSOM A DAMANIA, NANCY JOAN RAAB-TRAUB · 1985 to 2026
$43.8M
NCI NIH HHS 2-P01-CA19014-27NCI NIH HHS P01 CA019014NIAID NIH HHS P30 AI050410
6 · The paper itself

Abstract

Elevated levels of ubiquitin C-terminal hydrolase L1 (UCH L1) have been detected in a variety of malignancies, and recent studies show the oncogenic capacity of overexpressed UCH L1 in vivo in animal models. Here we demonstrate that expression of endogenous UCH L1 is significantly higher in B-lymphoma cells than in transformed cells of epithelial and fibroblastic origin. The specific hematopoietic transcription factor PU.1 induces UCH L1 expression through direct activation of the uch l1 promoter. Using chromatin immunoprecipitation (ChIP) assays and direct mutagenesis we identified PU.1 binding sites on the uch l1 promoter, at least three of which are involved in this activation. We also show that the viral transcriptional co-activator EBNA2 dramatically increases PU.1-dependent up-regulation of endogenous UCH L1 expression. Finally, inhibition of PU.1 expression with specific shRNA resulted in reduction of UCH L1 mRNA and protein levels in Epstein-Barr virus (EBV)-transformed B-cells. We propose that the ubiquitin-editing enzyme UCH L1 is a multifunctional pro-oncogenic factor involved in development and progression of certain lymphoid malignancies, including EBV-associated lymphomas.

Indexed as

Gene Expression Regulation, NeoplasticBinding SitesBurkitt LymphomaCell Line, TumorEndonucleasesHerpesvirus 4, HumanHumansLymphoma, B-CellModels, BiologicalNuclear ProteinsPromoter Regions, GeneticProtein BindingProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Trans-ActivatorsUbiquitin ThiolesteraseEndonucleasesNuclear ProteinsProto-Oncogene ProteinsProto-Oncogene Protein Spi-1SND1 protein, humanTrans-ActivatorsUbiquitin ThiolesteraseUCHL1 protein, human

Identifiers

PMID21504384
PMCPMC4435811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.